Induction of Corneal Endothelial Cells
- 技術優勢
- Unlike previously reported induction procedures, the present methods utilize a novel small molecule-based approach to derive human CECs along with three major retinal cell types, RPE, photoreceptor and RGC, from PSCs in a directional fate restriction fashion. Moreover, using EFSC-derived NCSCs as a starting cell source cell, CECs can be quickly and directly induced and expanded in culture.
- 技術應用
- A therapeutic composition and method for treating a patient in need of ocular therapy.A research tool comprising a feeder-free and serum-free culture of corneal endothelial cells (CECs). A method of identifying a pharmaceutically active agent, comprising combining a pharmaceutical candidate with a feeder-free and serum-free culture of corneal endothelial cells (CECs) and detecting a desired pharmaceutical activity, thereby identifying a pharmaceutically active agent.
- 詳細技術說明
- Researchers at UC San Diego have developed a small molecule based methodology to derive human CESs from PSCs via ocular lineage specification. A three-step strategy was employed; [1] eye field stem cells (EFSCs) were derived from PSCs, (2) EFSCs were directed to ocular neural crest stem cells (NCSC) fate, and (3) differentiated ocular NCSCs to human corneal endothelial cells (CECs) resulting in a homogeneous and expandable monolayer of CECs in culture.
- *Abstract
-
Ocular degenerative diseases including age-related macular degeneration (AMD), retinitis pigmentosa, glaucoma, and corneal endothelial dystrophy (CED) cause irreversible vision loss and affect millions of people worldwide. Currently, there is no effective drug intervention. Grafting healthy eye cells to replenish the diseased tissues such as retina represents a promising therapeutic approach. However, previous attempts at using primary human eye cells have met with limited success due to the limited expansion capacity and differentiation potential of adult progenitors or difficulty of obtaining sufficient human fetal retinal progenitors, and possible ethical concerns. Human pluripotent stem cells (PSCs), including human embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs) represent promising renewable donor sources for cell-based replacement therapy. Nevertheless, PSCs themselves are not suitable for direct transplantation in clinical applications due to their tendency to form teratomas and low efficiency in repopulating host tissues with desirable reprogrammed cell types in vivo.
While the advancement of clinical trials of hESC-derived RPE transplants for treatment of patients with Stargardt's macular dystrophy and AMD is encouraging to the field, there is a great need for methods of generating unlimited other specialized eye cells effectively in vitro for treating blindness due to the loss of photoreceptors, RGCs and CECs. Therefore, there is a major interest in development of in vitro expandable cell sources for engineering corneal endothelium.
- *Applications
-
- A therapeutic composition and method for treating a patient in need of ocular therapy.
- *IP Issue Date
- Nov 2, 2017
- *Principal Investigation
-
Name: Natalie Afshari
Department:
Name: Jiagang Zhao
Department:
- 其他
-
State Of Development
The current methodology provides a research tool for generating feeder and serum-free culture of CDCs. The majority of CECs expressed ZO-1, N-cadherin and Na+/K+ATPase, all characteristic markers of CECs.
Intellectual Property Info
Patent-pending. Worldwide rights are available.
Related Materials
Tech ID/UC Case
27338/2016-284-0
Related Cases
2016-284-0
- 國家/地區
- 美國
